Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Evaxion Biotech AS
EVAXCurrent price
2.64 USD
+0.09 USD (+3.53%)
Last closed
2.59 USD
Company
www.evaxion-biotech.com
ISIN
US29970R1059
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
14 447 175 USD
Yield for 12 month
-76.22 %
1Y
3Y
5Y
10Y
15Y
EVAX
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark. Address: Dr. Neergaards Vej, Horsholm, Denmark, 2970
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
10.85 USDP/E ratio
–Dividend Yield
–Current Year
+73 112 USD
Last Year
–
Current Quarter
+153 887 USD
Last Quarter
+50 881 USD
Current Year
+73 112 USD
Last Year
-571 319 USD
Current Quarter
+153 887 USD
Last Quarter
+50 881 USD
Key Figures EVAX
1 year
3 years
5 years
10 years
EBITDA
-14 873 750 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-69.45 %
PEG Ratio
–
Return On Equity TTM
-802.8 %
Wall Street Target Price
10.85 USD
Revenue TTM
3 295 000 USD
Book Value
0.013 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-4.5 USD
Diluted Eps TTM
-4.5 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics EVAX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History EVAX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:10
Payout Ratio
–
Last Split Date
22.01.2024
Dividend Date
–
Stock Valuation EVAX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
3.5714
Enterprise Value Revenue
60.9466
Price Sales TTM
4.3846
Enterprise Value EBITDA
-0.5929
Price Book MRQ
11.5301
Financials EVAX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators EVAX
For 52 weeks
2.26 USD
13.61 USD
50 Day MA
2.94 USD
Shares Short Prior Month
85 347
200 Day MA
3.45 USD
Short Ratio
0.72
Shares Short
67 408
Short Percent
1.69 %
BeatStart